Review





Similar Products

91
Bio-Techne corporation mouse/rat tlr7 antibody
Mouse/Rat Tlr7 Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tlr7/Mouse%2FRat+TLR7+Antibody/bio-techne+corporation___mab7156
Average 91 stars, based on 1 article reviews
mouse/rat tlr7 antibody - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

91
Novus Biologicals r848
Endothelial cell regulation of NFκB pathway-associated genes by Pam3CSK4, Poly I:C or <t> R848 </t> compared to control.
R848, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tlr7/Imidazoquinoline+Resiquimod+(R-848)%2C+TLR7+and+TLR8+ligand/pmc13759055-119-46-51
Average 91 stars, based on 1 article reviews
r848 - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

93
Proteintech tlr7
Primer sequences.
Tlr7, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tlr7/TLR7+Antibody/pmc13680207-140-8-22
Average 93 stars, based on 1 article reviews
tlr7 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Cell Signaling Technology Inc tlr7
Primer sequences.
Tlr7, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tlr7/Toll-like+Receptor+7+Rabbit+mAb/pm42815593-78-14-16
Average 94 stars, based on 1 article reviews
tlr7 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

99
InvivoGen tlr7 ligand gardiquimod
Primer sequences.
Tlr7 Ligand Gardiquimod, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tlr7/Gardiquimod/pm42695766-54-38-43
Average 99 stars, based on 1 article reviews
tlr7 ligand gardiquimod - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
InvivoGen tlr7 8 agonist r848
Primer sequences.
Tlr7 8 Agonist R848, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tlr7/R848/pm42668088-237-31-36
Average 99 stars, based on 1 article reviews
tlr7 8 agonist r848 - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
InvivoGen tlr7 agonist r848
Primer sequences.
Tlr7 Agonist R848, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tlr7/R848/pm42685608-113-7-10
Average 99 stars, based on 1 article reviews
tlr7 agonist r848 - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
InvivoGen r848 resiquimod tlr7 8 agonist

R848 Resiquimod Tlr7 8 Agonist, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tlr7/R848/pmc13522792-72-0-6
Average 99 stars, based on 1 article reviews
r848 resiquimod tlr7 8 agonist - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
InvivoGen tlr7 8 agonist

Tlr7 8 Agonist, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tlr7/R848/10__1038_slash_s41598___026___66036___9-132-43-47
Average 99 stars, based on 1 article reviews
tlr7 8 agonist - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

98
InvivoGen tlr7 antagonist m5049
a The FPKM expression of MARCO was plotted against TLR3 , <t>TLR7</t> and TLR9 in a subset of patients with melanoma included in the TCGA database. Correlation is shown in a xy-plot with a linear regression. P values were calculated by two-tailed Pearson’s correlation test. b The FPKM expression of MARCO was plotted against TLR3 , TLR7 and TLR9 in a subset of patients with breast cancer included in the TCGA database. P values were calculated by two-tailed Pearson’s correlation test. c Immunofluorescence analysis of triple-negative breast cancer (TNBC) from a cohort of n = 3 patients. Representative immunofluorescence images are shown for a patient who received neoadjuvant chemotherapy and went for operation. Scale bars, 100 μm (far-left) and 20 μm. d BMDMs from WT and Unc93b1 3d/3d mice were stimulated with the indicated components. Black: without stimulation; red: Poly I:C (TLR3 agonist) (1 μg/ml); purple: R848 (TLR7 agonist) (1 μg/ml); blue: CPG ODN (TLR9 agonist) (1 μM). Representative histograms showing the MARCO expression. e Representative graph showing the relative gene expression of Marco under the indicated components stimulation. n = 3 mice per group from one experiment. Data are summarized from three ( d , e ) independent experiments. Bar plots show mean ± s.e.m. P values were calculated by ordinary one-way ANOVA followed by Tukey’s post hoc test ( e ).
Tlr7 Antagonist M5049, supplied by InvivoGen, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tlr7/M5049/pmc13408345-411-17-20
Average 98 stars, based on 1 article reviews
tlr7 antagonist m5049 - by Bioz Stars, 2026-11
98/100 stars
  Buy from Supplier

Image Search Results


Endothelial cell regulation of NFκB pathway-associated genes by Pam3CSK4, Poly I:C or  R848  compared to control.

Journal: PLOS One

Article Title: Distinct transcriptional, cytokine, and γ-protocadherin responses to TLR1/2, TLR3, and TLR7/8 agonists in human cardiac endothelial cells

doi: 10.1371/journal.pone.0361988

Figure Lengend Snippet: Endothelial cell regulation of NFκB pathway-associated genes by Pam3CSK4, Poly I:C or R848 compared to control.

Article Snippet: Confluent cultures were exposed for 24 hours to one of the following agonists or to vehicle alone: 100 ng/ml Pam3CysSerLys4 (Pam3CSK4; TLR1/TLR2 heterodimer agonist, cat# NBP2-25297, Novus Biologicals, Centennial, CO), 100 μg/ml polyinosinic:polycytidylic acid (Poly I:C; TLR3 agonist, cat# NBP2-25288, Novus Biologicals, Centennial, CO), 5 μg/ml R848 (TLR7/TLR8 agonist, cat# NBP2-26231, Novus Biologicals, Centennial, CO), or 10 ng/ml lipopolysaccharide (LPS) from E. coli (Invivogen, San Diego, CA).

Techniques: Control

(A) Bar graph displaying relative expression levels of TLR1, TLR2, TLR3, TLR7 and TLR8 in untreated cardiac ECs, (B) Bar graph displaying relative expression levels of TLR1, TLR2, TLR3, TLR7 and TLR8 in ECs treated with Pam3CSK4, Poly I:C, R848, or LPS (reference stimulant) compared to untreated controls (dashed line). Bars show data as the mean and standard deviation (SD). n = 8, *p-value <0.05 (one-way ANOVA).

Journal: PLOS One

Article Title: Distinct transcriptional, cytokine, and γ-protocadherin responses to TLR1/2, TLR3, and TLR7/8 agonists in human cardiac endothelial cells

doi: 10.1371/journal.pone.0361988

Figure Lengend Snippet: (A) Bar graph displaying relative expression levels of TLR1, TLR2, TLR3, TLR7 and TLR8 in untreated cardiac ECs, (B) Bar graph displaying relative expression levels of TLR1, TLR2, TLR3, TLR7 and TLR8 in ECs treated with Pam3CSK4, Poly I:C, R848, or LPS (reference stimulant) compared to untreated controls (dashed line). Bars show data as the mean and standard deviation (SD). n = 8, *p-value <0.05 (one-way ANOVA).

Article Snippet: Confluent cultures were exposed for 24 hours to one of the following agonists or to vehicle alone: 100 ng/ml Pam3CysSerLys4 (Pam3CSK4; TLR1/TLR2 heterodimer agonist, cat# NBP2-25297, Novus Biologicals, Centennial, CO), 100 μg/ml polyinosinic:polycytidylic acid (Poly I:C; TLR3 agonist, cat# NBP2-25288, Novus Biologicals, Centennial, CO), 5 μg/ml R848 (TLR7/TLR8 agonist, cat# NBP2-26231, Novus Biologicals, Centennial, CO), or 10 ng/ml lipopolysaccharide (LPS) from E. coli (Invivogen, San Diego, CA).

Techniques: Expressing, Standard Deviation, Gene Expression

(A) PCA score plot (first three components) based on expression of the predefined panel of NF-κB pathway-associated genes, showing a separation between cardiac ECs treated with Pam3CSK4 (blue), Poly I:C (yellow) or R848 (red) and untreated control cells (green), (B) Heatmap showing expression patterns within the focused gene panel after stimulation with Pam3CSK4, Poly I:C, or R848 compared to untreated cells (controls). n = 4, log2 fold change.

Journal: PLOS One

Article Title: Distinct transcriptional, cytokine, and γ-protocadherin responses to TLR1/2, TLR3, and TLR7/8 agonists in human cardiac endothelial cells

doi: 10.1371/journal.pone.0361988

Figure Lengend Snippet: (A) PCA score plot (first three components) based on expression of the predefined panel of NF-κB pathway-associated genes, showing a separation between cardiac ECs treated with Pam3CSK4 (blue), Poly I:C (yellow) or R848 (red) and untreated control cells (green), (B) Heatmap showing expression patterns within the focused gene panel after stimulation with Pam3CSK4, Poly I:C, or R848 compared to untreated cells (controls). n = 4, log2 fold change.

Article Snippet: Confluent cultures were exposed for 24 hours to one of the following agonists or to vehicle alone: 100 ng/ml Pam3CysSerLys4 (Pam3CSK4; TLR1/TLR2 heterodimer agonist, cat# NBP2-25297, Novus Biologicals, Centennial, CO), 100 μg/ml polyinosinic:polycytidylic acid (Poly I:C; TLR3 agonist, cat# NBP2-25288, Novus Biologicals, Centennial, CO), 5 μg/ml R848 (TLR7/TLR8 agonist, cat# NBP2-26231, Novus Biologicals, Centennial, CO), or 10 ng/ml lipopolysaccharide (LPS) from E. coli (Invivogen, San Diego, CA).

Techniques: Expressing, Control

(A-C) Volcano plots generated using the QIAGEN PCR Array Data Analysis platform, displaying fold regulation and nominal p-values from two-tailed Student’s t-tests for Pam3CSK4 (A), Poly I:C (B) or R848 (C) compared to untreated cells. n = 4, log2 fold change, p-value <0.05 (t-test).

Journal: PLOS One

Article Title: Distinct transcriptional, cytokine, and γ-protocadherin responses to TLR1/2, TLR3, and TLR7/8 agonists in human cardiac endothelial cells

doi: 10.1371/journal.pone.0361988

Figure Lengend Snippet: (A-C) Volcano plots generated using the QIAGEN PCR Array Data Analysis platform, displaying fold regulation and nominal p-values from two-tailed Student’s t-tests for Pam3CSK4 (A), Poly I:C (B) or R848 (C) compared to untreated cells. n = 4, log2 fold change, p-value <0.05 (t-test).

Article Snippet: Confluent cultures were exposed for 24 hours to one of the following agonists or to vehicle alone: 100 ng/ml Pam3CysSerLys4 (Pam3CSK4; TLR1/TLR2 heterodimer agonist, cat# NBP2-25297, Novus Biologicals, Centennial, CO), 100 μg/ml polyinosinic:polycytidylic acid (Poly I:C; TLR3 agonist, cat# NBP2-25288, Novus Biologicals, Centennial, CO), 5 μg/ml R848 (TLR7/TLR8 agonist, cat# NBP2-26231, Novus Biologicals, Centennial, CO), or 10 ng/ml lipopolysaccharide (LPS) from E. coli (Invivogen, San Diego, CA).

Techniques: Generated, Analysis, Two Tailed Test

Cytokine levels were measured in conditioned medium following treatment of cardiac ECs with Pam3CSK4, Poly I:C or R848 and compared to medium from untreated cells (controls). Bars show data as the mean and standard deviation (SD). n = 7-8. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (one way ANOVA).

Journal: PLOS One

Article Title: Distinct transcriptional, cytokine, and γ-protocadherin responses to TLR1/2, TLR3, and TLR7/8 agonists in human cardiac endothelial cells

doi: 10.1371/journal.pone.0361988

Figure Lengend Snippet: Cytokine levels were measured in conditioned medium following treatment of cardiac ECs with Pam3CSK4, Poly I:C or R848 and compared to medium from untreated cells (controls). Bars show data as the mean and standard deviation (SD). n = 7-8. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (one way ANOVA).

Article Snippet: Confluent cultures were exposed for 24 hours to one of the following agonists or to vehicle alone: 100 ng/ml Pam3CysSerLys4 (Pam3CSK4; TLR1/TLR2 heterodimer agonist, cat# NBP2-25297, Novus Biologicals, Centennial, CO), 100 μg/ml polyinosinic:polycytidylic acid (Poly I:C; TLR3 agonist, cat# NBP2-25288, Novus Biologicals, Centennial, CO), 5 μg/ml R848 (TLR7/TLR8 agonist, cat# NBP2-26231, Novus Biologicals, Centennial, CO), or 10 ng/ml lipopolysaccharide (LPS) from E. coli (Invivogen, San Diego, CA).

Techniques: Standard Deviation

Bar graph displaying relative expression levels of γ-protocadherin genes. The dashed line indicates gene expression levels of untreated cardiac ECs (controls), bars represent gene expression levels of ECs treated with Pam3CSK4, Poly I:C, R848 or LPS (reference stimulant). Bars show data as the mean and standard deviation (SD). n = 8, *p-value <0.05 (one way ANOVA).

Journal: PLOS One

Article Title: Distinct transcriptional, cytokine, and γ-protocadherin responses to TLR1/2, TLR3, and TLR7/8 agonists in human cardiac endothelial cells

doi: 10.1371/journal.pone.0361988

Figure Lengend Snippet: Bar graph displaying relative expression levels of γ-protocadherin genes. The dashed line indicates gene expression levels of untreated cardiac ECs (controls), bars represent gene expression levels of ECs treated with Pam3CSK4, Poly I:C, R848 or LPS (reference stimulant). Bars show data as the mean and standard deviation (SD). n = 8, *p-value <0.05 (one way ANOVA).

Article Snippet: Confluent cultures were exposed for 24 hours to one of the following agonists or to vehicle alone: 100 ng/ml Pam3CysSerLys4 (Pam3CSK4; TLR1/TLR2 heterodimer agonist, cat# NBP2-25297, Novus Biologicals, Centennial, CO), 100 μg/ml polyinosinic:polycytidylic acid (Poly I:C; TLR3 agonist, cat# NBP2-25288, Novus Biologicals, Centennial, CO), 5 μg/ml R848 (TLR7/TLR8 agonist, cat# NBP2-26231, Novus Biologicals, Centennial, CO), or 10 ng/ml lipopolysaccharide (LPS) from E. coli (Invivogen, San Diego, CA).

Techniques: Expressing, Gene Expression, Standard Deviation

Primer sequences.

Journal: Frontiers in Immunology

Article Title: Integrated multi-omics and machine learning identify core mechanobiology-associated immune genes in pulmonary arterial hypertension

doi: 10.3389/fimmu.2026.1867114

Figure Lengend Snippet: Primer sequences.

Article Snippet: The primary antibodies utilized in this study included: TLR7 (17232-1-AP), CD86 (26903-1-AP), CD83 (27873-1-AP), IL-6 (21865-1-AP), and α-Tubulin (80762-1-RR), all purchased from Proteintech, Rosemont, USA.

Techniques:

Transparent candidate prioritization and diagnostic value of the experimentally examined four-gene panel. (A) Candidate funnel from mechanical source genes to PAH-MRG overlap, variable PAH-MRG genes, machine-learning-stable candidates and the four-gene panel. (B) LASSO coefficient paths and random-forest importance. (C) Shapley contribution of CD83, CD86, IL6 and TLR7 in the four-gene logistic model. (D) Cross-layer direction of the four genes in lung bulk, PBMC and single-cell data. (E) Single-cell expression across cell types. (F) Four-gene disease-state score ROC and calibration. (G) Per-gene ROC curves in lung and PBMC. The ML component is presented as candidate prioritization rather than a deployable diagnostic model.

Journal: Frontiers in Immunology

Article Title: Integrated multi-omics and machine learning identify core mechanobiology-associated immune genes in pulmonary arterial hypertension

doi: 10.3389/fimmu.2026.1867114

Figure Lengend Snippet: Transparent candidate prioritization and diagnostic value of the experimentally examined four-gene panel. (A) Candidate funnel from mechanical source genes to PAH-MRG overlap, variable PAH-MRG genes, machine-learning-stable candidates and the four-gene panel. (B) LASSO coefficient paths and random-forest importance. (C) Shapley contribution of CD83, CD86, IL6 and TLR7 in the four-gene logistic model. (D) Cross-layer direction of the four genes in lung bulk, PBMC and single-cell data. (E) Single-cell expression across cell types. (F) Four-gene disease-state score ROC and calibration. (G) Per-gene ROC curves in lung and PBMC. The ML component is presented as candidate prioritization rather than a deployable diagnostic model.

Article Snippet: The primary antibodies utilized in this study included: TLR7 (17232-1-AP), CD86 (26903-1-AP), CD83 (27873-1-AP), IL-6 (21865-1-AP), and α-Tubulin (80762-1-RR), all purchased from Proteintech, Rosemont, USA.

Techniques: Diagnostic Assay, Single Cell, Expressing

Single-cell localization of the four-gene panel. (A) UMAP visualization of annotated lung cell types split by control and IPAH status. (B) Cellular composition comparison between control and IPAH. (C) Canonical marker dot plot supporting cell-type annotation. (D) Feature plots and violin plots showing CD83, CD86, IL6 and TLR7 expression across disease groups. CD83 and CD86 localize mainly to myeloid/macrophage and antigen-presenting compartments, whereas IL6 shows structural-cell enrichment and TLR7 is sparsely detected.

Journal: Frontiers in Immunology

Article Title: Integrated multi-omics and machine learning identify core mechanobiology-associated immune genes in pulmonary arterial hypertension

doi: 10.3389/fimmu.2026.1867114

Figure Lengend Snippet: Single-cell localization of the four-gene panel. (A) UMAP visualization of annotated lung cell types split by control and IPAH status. (B) Cellular composition comparison between control and IPAH. (C) Canonical marker dot plot supporting cell-type annotation. (D) Feature plots and violin plots showing CD83, CD86, IL6 and TLR7 expression across disease groups. CD83 and CD86 localize mainly to myeloid/macrophage and antigen-presenting compartments, whereas IL6 shows structural-cell enrichment and TLR7 is sparsely detected.

Article Snippet: The primary antibodies utilized in this study included: TLR7 (17232-1-AP), CD86 (26903-1-AP), CD83 (27873-1-AP), IL-6 (21865-1-AP), and α-Tubulin (80762-1-RR), all purchased from Proteintech, Rosemont, USA.

Techniques: Single Cell, Control, Comparison, Marker, Expressing, Gene Expression

Establishment of MCT-induced pulmonary hypertension (PH) rat model recapitulating PAH pathological features. (A) RVSP and (B) RV/(LV+S) were detected in MCT-induced pulmonary hypertension (PH) rats and control rats (n=6/group). (C) Representative H&E staining images of lung tissues from the two groups. Black asterisks mark the pulmonary artery lumen. Scale bar = 100 μm (n=6/group). (D) Representative Western blot bands and quantitative analysis of CD86, TLR7, CD83, IL-6, and GAPDH in lung tissues of MCT-induced PH rats and control rats. Data represent mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 compared to control, as analyzed by unpaired t test or Mann-Whitney test as appropriate.

Journal: Frontiers in Immunology

Article Title: Integrated multi-omics and machine learning identify core mechanobiology-associated immune genes in pulmonary arterial hypertension

doi: 10.3389/fimmu.2026.1867114

Figure Lengend Snippet: Establishment of MCT-induced pulmonary hypertension (PH) rat model recapitulating PAH pathological features. (A) RVSP and (B) RV/(LV+S) were detected in MCT-induced pulmonary hypertension (PH) rats and control rats (n=6/group). (C) Representative H&E staining images of lung tissues from the two groups. Black asterisks mark the pulmonary artery lumen. Scale bar = 100 μm (n=6/group). (D) Representative Western blot bands and quantitative analysis of CD86, TLR7, CD83, IL-6, and GAPDH in lung tissues of MCT-induced PH rats and control rats. Data represent mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 compared to control, as analyzed by unpaired t test or Mann-Whitney test as appropriate.

Article Snippet: The primary antibodies utilized in this study included: TLR7 (17232-1-AP), CD86 (26903-1-AP), CD83 (27873-1-AP), IL-6 (21865-1-AP), and α-Tubulin (80762-1-RR), all purchased from Proteintech, Rosemont, USA.

Techniques: Control, Staining, Western Blot, Analysis, MANN-WHITNEY

Biomarker validation in clinical IPAH peripheral blood mononuclear cell specimens. (A) Expression levels of CD86, TLR7, CD83 and IL-6 in clinical peripheral blood mononuclear cell (PBMC) samples. (B) ROC curve analysis of the diagnostic efficacy of CD86, TLR7, CD83 and IL-6 for IPAH. Data represent mean ± SEM. *** P < 0.001 compared to control, as analyzed by unpaired t test.

Journal: Frontiers in Immunology

Article Title: Integrated multi-omics and machine learning identify core mechanobiology-associated immune genes in pulmonary arterial hypertension

doi: 10.3389/fimmu.2026.1867114

Figure Lengend Snippet: Biomarker validation in clinical IPAH peripheral blood mononuclear cell specimens. (A) Expression levels of CD86, TLR7, CD83 and IL-6 in clinical peripheral blood mononuclear cell (PBMC) samples. (B) ROC curve analysis of the diagnostic efficacy of CD86, TLR7, CD83 and IL-6 for IPAH. Data represent mean ± SEM. *** P < 0.001 compared to control, as analyzed by unpaired t test.

Article Snippet: The primary antibodies utilized in this study included: TLR7 (17232-1-AP), CD86 (26903-1-AP), CD83 (27873-1-AP), IL-6 (21865-1-AP), and α-Tubulin (80762-1-RR), all purchased from Proteintech, Rosemont, USA.

Techniques: Biomarker Discovery, Expressing, Analysis, Diagnostic Assay, Control

Journal: Cell Reports Medicine

Article Title: Tumor-induced dendritic cell deregulation perturbs T cell proliferation and predicts clinical outcome in acute lymphoblastic leukemia

doi: 10.1016/j.xcrm.2026.102945

Figure Lengend Snippet:

Article Snippet: R848 (Resiquimod) - TLR7/8 Agonist , InvivoGen , Cat# tlrl-r848-1; RRID: N/A.

Techniques: Recombinant, Flow Cytometry, Staining, Cell Isolation, Single Cell, Amplification, Gene Expression, Software

a The FPKM expression of MARCO was plotted against TLR3 , TLR7 and TLR9 in a subset of patients with melanoma included in the TCGA database. Correlation is shown in a xy-plot with a linear regression. P values were calculated by two-tailed Pearson’s correlation test. b The FPKM expression of MARCO was plotted against TLR3 , TLR7 and TLR9 in a subset of patients with breast cancer included in the TCGA database. P values were calculated by two-tailed Pearson’s correlation test. c Immunofluorescence analysis of triple-negative breast cancer (TNBC) from a cohort of n = 3 patients. Representative immunofluorescence images are shown for a patient who received neoadjuvant chemotherapy and went for operation. Scale bars, 100 μm (far-left) and 20 μm. d BMDMs from WT and Unc93b1 3d/3d mice were stimulated with the indicated components. Black: without stimulation; red: Poly I:C (TLR3 agonist) (1 μg/ml); purple: R848 (TLR7 agonist) (1 μg/ml); blue: CPG ODN (TLR9 agonist) (1 μM). Representative histograms showing the MARCO expression. e Representative graph showing the relative gene expression of Marco under the indicated components stimulation. n = 3 mice per group from one experiment. Data are summarized from three ( d , e ) independent experiments. Bar plots show mean ± s.e.m. P values were calculated by ordinary one-way ANOVA followed by Tukey’s post hoc test ( e ).

Journal: Nature Communications

Article Title: Cancer immunotherapy targeting murine myeloid cells requires endosomal pattern recognition

doi: 10.1038/s41467-026-75543-2

Figure Lengend Snippet: a The FPKM expression of MARCO was plotted against TLR3 , TLR7 and TLR9 in a subset of patients with melanoma included in the TCGA database. Correlation is shown in a xy-plot with a linear regression. P values were calculated by two-tailed Pearson’s correlation test. b The FPKM expression of MARCO was plotted against TLR3 , TLR7 and TLR9 in a subset of patients with breast cancer included in the TCGA database. P values were calculated by two-tailed Pearson’s correlation test. c Immunofluorescence analysis of triple-negative breast cancer (TNBC) from a cohort of n = 3 patients. Representative immunofluorescence images are shown for a patient who received neoadjuvant chemotherapy and went for operation. Scale bars, 100 μm (far-left) and 20 μm. d BMDMs from WT and Unc93b1 3d/3d mice were stimulated with the indicated components. Black: without stimulation; red: Poly I:C (TLR3 agonist) (1 μg/ml); purple: R848 (TLR7 agonist) (1 μg/ml); blue: CPG ODN (TLR9 agonist) (1 μM). Representative histograms showing the MARCO expression. e Representative graph showing the relative gene expression of Marco under the indicated components stimulation. n = 3 mice per group from one experiment. Data are summarized from three ( d , e ) independent experiments. Bar plots show mean ± s.e.m. P values were calculated by ordinary one-way ANOVA followed by Tukey’s post hoc test ( e ).

Article Snippet: To assess the contribution of TLR for inflammasome activation, mouse PMs were stimulated with either 1 μM TLR7 antagonist M5049 (Invivogen, #inh-m5049) or 1 μM TLR9 antagonist ODN INH-18 (Invivogen, #tlrl-inh18) for 6 h, followed by 6 h tumor-conditional media stimulation and ATP (5 mM) was added for the last 30 min for stimulation.

Techniques: Expressing, Two Tailed Test, Immunofluorescence, Gene Expression

a ATP release upon αMARCO antibody stimulation of peritoneal macrophages (PM). Data have been subtracted from the baseline level. n = 3 mice per group. b Spleens from Tlr9 flox/flox , Unc93b1 3d/3d and Marco Cre+/− Tlr9 flox/flox mice injected (i.v.) with control or αMARCO (50 μg/mouse) for 24 h. Dot plots showing the percentage of CD21 + cells on marginal zone B cell (MZB). c The expression of CD21 on MZB gated using CD1d. Tlr9 flox/flox Ctrl n = 5, Tlr9 flox/flox αMARCO n = 6, Unc93b1 3d/3d Ctrl n = 7, Unc93b1 3d/3d αMARCO n = 7, Marco Cre+/− Tlr9 flox/flox Ctrl n = 6, Marco Cre+/− Tlr9 flox/flox αMARCO n = 6. d Relative expression of Il-1β , Nlrp3 , Il-18 , and Ifnβ on PMs from WT mice stimulated with or without CPG ODN (TLR9 agonist) (1 μM) for 12 h. n = 4 mice per group. e Relative expression of Il-1β and Nlrp3 on PMs stimulated with CPG ODN (1 μM) for 12 h. n = 4 mice per group. f Relative expression of Il-1β and Nlrp3 on PMs stimulated with tumor-conditioned media for 12 h. g Western blot analysis of inflammasome-related proteins in PMs isolated from Tlr9 flox/flox and Marco Cre+/− Tlr9 flox/flox mice. h The percent of FLICA+ macrophage in PMs. n = 4 mice per group. Data have been subtracted from the baseline level. i IL-1β levels detected in the supernatant of PMs stimulated with CPG ODN (1 μM) for 12 h following with ATP (5 mM). n = 4 mice per group. j IL-1β levels detected in the supernatant of PMs stimulated with tumor-conditioned media for 12 h following with ATP (5 mM). n = 4 mice per group. k IL-1β levels detected in the supernatant of WT PMs stimulated with indicate reagents for 12 h following with ATP (5 mM). n = 4 mice per group. l IL-1β levels detected in the supernatant of WT PMs pretreated with M5049 (1 μM) or ODN INH-18 (1 μM) for 6 h followed with tumor-conditioned media for 6 h and stimulated with ATP (5 mM). n = 8 mice per group. m IL-1β levels detected in the supernatant of B16-F10 tumor-conditioned media after 24 h cultured. n = 4 mice per group. n IL-1β levels detected in the supernatant of EO771 tumor-conditioned media after 24 h cultured. Tlr9 flox/flox n = 5, Marco Cre+/− Tlr9 flox/flox n = 4. Representative graph shows one representative experiment out of two ( a – c , g–n ) and three ( d – f ) independent repeats. Dots represent biological replicates ( a , c – f , h–n ). Bar plots show mean ± s.e.m. P values were calculated by two-side Mann–Whitney U test.

Journal: Nature Communications

Article Title: Cancer immunotherapy targeting murine myeloid cells requires endosomal pattern recognition

doi: 10.1038/s41467-026-75543-2

Figure Lengend Snippet: a ATP release upon αMARCO antibody stimulation of peritoneal macrophages (PM). Data have been subtracted from the baseline level. n = 3 mice per group. b Spleens from Tlr9 flox/flox , Unc93b1 3d/3d and Marco Cre+/− Tlr9 flox/flox mice injected (i.v.) with control or αMARCO (50 μg/mouse) for 24 h. Dot plots showing the percentage of CD21 + cells on marginal zone B cell (MZB). c The expression of CD21 on MZB gated using CD1d. Tlr9 flox/flox Ctrl n = 5, Tlr9 flox/flox αMARCO n = 6, Unc93b1 3d/3d Ctrl n = 7, Unc93b1 3d/3d αMARCO n = 7, Marco Cre+/− Tlr9 flox/flox Ctrl n = 6, Marco Cre+/− Tlr9 flox/flox αMARCO n = 6. d Relative expression of Il-1β , Nlrp3 , Il-18 , and Ifnβ on PMs from WT mice stimulated with or without CPG ODN (TLR9 agonist) (1 μM) for 12 h. n = 4 mice per group. e Relative expression of Il-1β and Nlrp3 on PMs stimulated with CPG ODN (1 μM) for 12 h. n = 4 mice per group. f Relative expression of Il-1β and Nlrp3 on PMs stimulated with tumor-conditioned media for 12 h. g Western blot analysis of inflammasome-related proteins in PMs isolated from Tlr9 flox/flox and Marco Cre+/− Tlr9 flox/flox mice. h The percent of FLICA+ macrophage in PMs. n = 4 mice per group. Data have been subtracted from the baseline level. i IL-1β levels detected in the supernatant of PMs stimulated with CPG ODN (1 μM) for 12 h following with ATP (5 mM). n = 4 mice per group. j IL-1β levels detected in the supernatant of PMs stimulated with tumor-conditioned media for 12 h following with ATP (5 mM). n = 4 mice per group. k IL-1β levels detected in the supernatant of WT PMs stimulated with indicate reagents for 12 h following with ATP (5 mM). n = 4 mice per group. l IL-1β levels detected in the supernatant of WT PMs pretreated with M5049 (1 μM) or ODN INH-18 (1 μM) for 6 h followed with tumor-conditioned media for 6 h and stimulated with ATP (5 mM). n = 8 mice per group. m IL-1β levels detected in the supernatant of B16-F10 tumor-conditioned media after 24 h cultured. n = 4 mice per group. n IL-1β levels detected in the supernatant of EO771 tumor-conditioned media after 24 h cultured. Tlr9 flox/flox n = 5, Marco Cre+/− Tlr9 flox/flox n = 4. Representative graph shows one representative experiment out of two ( a – c , g–n ) and three ( d – f ) independent repeats. Dots represent biological replicates ( a , c – f , h–n ). Bar plots show mean ± s.e.m. P values were calculated by two-side Mann–Whitney U test.

Article Snippet: To assess the contribution of TLR for inflammasome activation, mouse PMs were stimulated with either 1 μM TLR7 antagonist M5049 (Invivogen, #inh-m5049) or 1 μM TLR9 antagonist ODN INH-18 (Invivogen, #tlrl-inh18) for 6 h, followed by 6 h tumor-conditional media stimulation and ATP (5 mM) was added for the last 30 min for stimulation.

Techniques: Injection, Control, Expressing, Western Blot, Isolation, Cell Culture, MANN-WHITNEY